Initial prescription of #tramadol associated with > mortality vs #nsaids over 1 year follow up #EULAR2019 https://t.co/moBAohdkBx
— Evan Vista, MD (@evanvistamd) June 13, 2019
Riociquat in Scleroderma ILD. Almost worked on skin, but did work in those with ILD. OP0183 #EULAR2019 https://t.co/ySHQxOCrb5
— Dr. John Cush (@RheumNow) June 13, 2019
I hate the term “appropriate.” It’s meaningless or stands as a flag for moral/social/radical and cultural prejudice. Same with “rude.” So interpret it however you want.
— Medical Axioms (@medicalaxioms) June 13, 2019
Six weeks of low-dose prednisolone improved #Pain and function in hand #osteoarthritis according to data presented at #EULAR19 https://t.co/SKndJfojFw
— Healio Rheumatology (@HealioRheum) June 13, 2019
2019 EULAR/ACR #lupus #classification #criteria#EULAR19 pic.twitter.com/PzuFUNgCs5
— dr hanady manasfi (@hanadymanasfi) June 13, 2019
The always eloquent Raashid Luqmani holds a full plenary hall entranced with an AAV masterclass #EULAR2019 SP0044 @RheumNow pic.twitter.com/sJ97QswXOY
— David Liew (@drdavidliew) June 13, 2019
Free Special Article in both A&R/AC&R #EULAR19
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitishttps://t.co/Ymu64QhV1G pic.twitter.com/9vwfb5CWbZ
— ACR_Journals (@ACR_Journals) June 13, 2019
Schulert, et al showed some beautiful work dissecting what drives monocytes and macrophages to go berzerk during Macrophage Activation Syndrome. Via transcriptional profiling, they find TRIM8 (E3 upiquitinligase) drives excessive IFNγ & is elevated in sJIA pts #EULAR2019 OP0150 pic.twitter.com/A7ziCjcGhC
— Dr. John Cush (@RheumNow) June 13, 2019
How do you treat Takyasu's arthritis at onset?
— Janet Pope (@Janetbirdope) June 13, 2019
How do you treat Hand Osteoarthritis?
— Dr. John Cush (@RheumNow) June 13, 2019
Take a look at one of our posters published during #EULAR2019 about Cannabis-based products for medicinal use in people with #fibromyalgia. #BecomeFibroAwarehttps://t.co/fvomc315o8 pic.twitter.com/71gPPEsohT
— Simon Stones (@SimonRStones) June 13, 2019
KAWAKINRA Study – Anakinra in IVIG Refractory Kawasaki Disease. #EULAR2019 Abstract OP0147 https://t.co/eVEAKIbho7
— Dr. John Cush (@RheumNow) June 13, 2019
Useful data regarding switch in RA!
JAKi to TNFi
or
TNFi to JAKin the one trial #eular2019 pic.twitter.com/2EViLJuCH1
— Dr Irwin Lim (@_connectedcare) June 12, 2019
Nearly 60% of patients with #Arthritis reported using #cannabidiol products to relieve #pain and other symptoms despite limited evidence showing efficacy of these products #EULAR19 https://t.co/Olzwi8ttD8
— Healio Rheumatology (@HealioRheum) June 13, 2019
John Stone reports that 42% of patients maintained treatment-free remission after 1 year of weekly tocilizumab in part 2 of the GiACTA trial. GC exposure over 3 years also lower #EULAR2019 #GiantCellArteritis pic.twitter.com/XpFyRj9wrx
— The Lancet Rheumatology (@TheLancetRheum) June 13, 2019
REMINDER: TWEETUP🙂 FRIDAY 1500 at STAND V08 BSR #eular2019 https://t.co/JlCg5g4lTj
— Dr Irwin Lim (@_connectedcare) June 13, 2019
TAkayasu's arteritis guidelines. Better studies needed THU0286 #EULAR2019 @RheumNow https://t.co/KQITL1ldtZ pic.twitter.com/iyMsfoIhTl
— Janet Pope (@Janetbirdope) June 13, 2019
Sjogren’s syndrome is associated with lymphoma, but we know not everyone has equal risk. Who should we worry about? Some suggestions from Vall d’Hebron, Barcelona#EULAR2019 SP0082 Albert Selva-O’Callaghan @RheumNow pic.twitter.com/XAmnZnl2fY
— David Liew (@drdavidliew) June 13, 2019
Georg Schett: The relationship bw facet joint disease and syndesmophytes has previously been recognised. IL23 blockade is very effective on enthaesitis and possibly has effect on axial enthaesitis. #eular2019
— Alberta Hoi (@tuna0sashimi) June 13, 2019
No new safety signals with 7 yrs LTE if Baricitinib in RA. Lack of VTE and Cv signal. THU0078 #EULAR2019 @RheumNow pic.twitter.com/aQDEwqoAk0
— Janet Pope (@Janetbirdope) June 13, 2019
#treatment in #extrarenal #lupus#EULAR19 pic.twitter.com/IMXzVcieMV
— dr hanady manasfi (@hanadymanasfi) June 13, 2019
How do pts do with CTD ILD after lung transplant. Study shows a trend to less survival than IPF. CTD pts slightly younger 56.5 vs IPF 60 yrs and more females 69% vs 23%. N of each group only 26. PIttsburg found increase early mortality then equal. OP0169 #EULAR2019 @RheumNow pic.twitter.com/7StbQ9U2g8
— Janet Pope (@Janetbirdope) June 13, 2019